What is the optimal management of thromboprophylaxis after liver transplantation regarding prevention of bleeding, hepatic artery or portal vein thrombosis? A systematic review of the literature and expert panel recommendations.
Varvara A KirchnerKi Won SongCharles ImberLucas McCormackPatrick G NorthupGi-Won SongMichael SpiroDimitri A RaptisFrançois DurandPublished in: Clinical transplantation (2022)
Based on existing data and expert opinion, thromboprophylaxis at therapeutic or prophylactic dose is not recommended for prevention of de novo PVT following LT in patients not at high risk. Aspirin should be considered as the standard of care following LT to prevent HAT. Thromboprophylaxis should be strongly considered in recipients at risk of HAT and PVT following LT. This article is protected by copyright. All rights reserved.
Keyphrases
- venous thromboembolism
- end stage renal disease
- clinical practice
- direct oral anticoagulants
- healthcare
- newly diagnosed
- ejection fraction
- chronic kidney disease
- low dose
- prognostic factors
- atrial fibrillation
- pulmonary embolism
- peritoneal dialysis
- type diabetes
- electronic health record
- big data
- coronary artery disease
- antiplatelet therapy
- kidney transplantation
- artificial intelligence
- chronic pain
- affordable care act